Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo with best supportive care in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.
Yoshino says that TAS-102 is well tolerated overall with very mild toxicity. The most common adverse events observed in the TAS-102 arm were hematologic, including anemia (16.5%) and neutropenia (34.9%).
There were also some incidences of diarrhea, pyrexia and vomiting, Yoshino says, but these were generally manageable. Based on this, Yoshino says he believes that TAS-102 is very well tolerated in almost all patients.
<<< View more from the 2014 World GI Congress